Integra LifeSciences (NASDAQ:IART) Hits New 1-Year High – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $18.19 and last traded at $17.9450, with a volume of 27101 shares traded. The stock had previously closed at $17.77.

Analyst Ratings Changes

Several equities research analysts have issued reports on IART shares. Argus restated a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and raised their price target for the company from $11.00 to $16.00 in a research note on Thursday, May 28th. Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Wells Fargo & Company raised their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Reduce” and a consensus price target of $14.00.

Integra LifeSciences Price Performance

The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -2.78, a PEG ratio of 1.23 and a beta of 1.24. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The company has a fifty day simple moving average of $13.28 and a two-hundred day simple moving average of $12.20.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same quarter last year, the company posted $0.41 EPS. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences in the fourth quarter worth approximately $25,000. Osaic Holdings Inc. boosted its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Integra LifeSciences by 145.9% during the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 3,742 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Integra LifeSciences during the 4th quarter worth approximately $124,000. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.